Transient Gene Therapy as Broad Spectrum Antiviral
瞬时基因疗法作为广谱抗病毒药物
基本信息
- 批准号:10324302
- 负责人:
- 金额:$ 25.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2022-09-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAnimal ModelAnimalsAntiviral AgentsAntiviral resistanceBiological ProcessBiotechnologyCOVID-19Cell LineCellsCessation of lifeComplexCoronavirusDataDevelopmentDoseEmergency SituationFDA approvedFormulationGeneral PopulationGenesGerm-Line MutationGoalsHamster Cell LineHamstersHospitalizationHumanHuman Cell LineISG15 geneImmune systemIn VitroIncidenceIndividualInfectionInflammationInfluenzaInfluenza A virusInheritedInterferon Type IInterferonsKnock-outKnowledgeLaboratoriesLeadLicensingMapsMessenger RNAMorbidity - disease rateMusMutationNatural ImmunityOutcomePharmaceutical PreparationsPharmacologic SubstancePhaseProteinsReadinessRegulationResistanceRoleSARS-CoV-2 infectionSafetySmall Business Technology Transfer ResearchSymptomsSystemTailTarget PopulationsTechnologyTestingTherapeuticVaccinesViralVirusVirus DiseasesVirus ReplicationVulnerable PopulationsWorkanti-influenzabasecommercial applicationcytokinedrug candidateflugene therapyhigh riskin vivoin vivo evaluationmedical schoolsmortalitynanoparticlenovelnovel therapeuticspatient populationphase 1 studyphase 2 studyresistant strainvaccine access
项目摘要
Project Summary
Currently there are very few antiviral drugs, and no broad-spectrum antiviral drugs. For example, Influenza A
virus (IAV) causes 12,000-56,000 deaths and 150,000-750,000 hospitalizations annually in the US alone, despite
the availability of vaccines and five FDA-approved drugs 1, 2. Resistance to two of the five existing drugs has
already emerged 13. Second, SARS-CoV-2 a virus which causes COVID19 led to unprecedented death toll
worldwide. Currently there are no anti-SARS-Cov-2 drugs that can target other corona viruses.
Type I interferons (IFNs) are host cytokines providing protection against viral infections. There are several
different layers of IFN negative regulation, and the ISG15/USP 18 host protein 4, 5, 6, 7 complex is responsible for
suppressing the tail end of IFN inflammation. Human ISG15 knockouts have been identified and shown to control
IAV and SARS-CoV-2 replication better than WT counterparts.
Based on the evidence of efficacy and safety provided by these ISG15-deficient individuals, Lab11 Therapeutics
is developing new drugs, transient host-mimicking modified mRNA therapies aimed at enhancing control of IAV
and SARS-CoV-2 infection in the general population 4, 6, 7. Candidate drugs are recreating antiviral state identified
and tested in the human system, but, for FDA approval, Lab11 Therapeutics must demonstrate safety and
efficacy in an animal model, before proceeding with human in vivo studies.
This STTR aims to test our modRNA cocktail drugs in animal models of IAV and SARS-CoV2 infection. The
phase I hypothesis is that modRNA cocktail delivered intranasally will restrict IAV replication in mice and SARS-
CoV-2 infection in hamsters. We will test this hypothesis in Specific Aim 1, by evaluating the effects of modRNAs
on IAV in human and murine cell lines followed by in vivo testing in mice. In Specific Aim 2, we will evaluate the
effects modRNAs have on SARS-CoV-2 in human and hamster cell lines followed by in vivo testing in hamsters.
In Phase II, we propose to test different delivery modes and encapsulations of modRNAs to optimize the most
effective delivery and antiviral protection.
The global influenza market is valued at about 5 billion dollars, about a fifth of which relates to non-vaccine
products. The patient population targeted by Lab11 Therapeutics will be hundreds of millions of individuals in
the general population. Given the crucial role of IFN in the control of many viral infections (ISG15-deficient cells
control have been shown to control the replication of 14 different viruses more effectively than WT cells), the
lead drugs developed here for IAV and SARS-CoV2 are likely to be effective against other viral diseases too.
This will provide Lab11 Therapeutics with opportunities for the licensing of different products with identical
mechanisms of action on an indication-by-indication basis.
项目摘要
目前抗病毒药物很少,没有广谱抗病毒药物。例如,甲型流感
仅在美国,IAV病毒(IAV)每年就导致12,000 - 56,000人死亡和150,000 - 750,000人住院治疗,尽管
疫苗和五种FDA批准的药物的可用性1,2.对五种现有药物中的两种产生耐药性,
已经出现13.第二,SARS-CoV-2是一种导致COVID-19的病毒,导致了前所未有的死亡人数
国际吧目前还没有针对其他冠状病毒的抗SARS-Cov-2药物。
I型干扰素(IFN)是提供针对病毒感染的保护的宿主细胞因子。有几
IFN负调控的不同层,ISG 15/USP 18宿主蛋白4、5、6、7复合物负责
抑制IFN炎症的尾端。已经鉴定了人ISG 15敲除,并显示其控制
IAV和SARS-CoV-2复制优于WT对应物。
基于这些ISG 15缺陷个体提供的有效性和安全性证据,Lab 11 Therapeutics
正在开发新的药物,旨在增强IAV控制的瞬时宿主模拟修饰mRNA疗法
和普通人群中的SARS-CoV-2感染4,6,7.候选药物正在重建已确定的抗病毒状态
并在人体系统中进行了测试,但是,为了获得FDA的批准,Lab 11 Therapeutics必须证明其安全性,
在进行人体体内研究之前,在动物模型中进行有效性研究。
该STTR旨在在IAV和SARS-CoV 2感染的动物模型中测试我们的modRNA鸡尾酒药物。的
第一阶段的假设是,modRNA鸡尾酒鼻内递送将限制IAV在小鼠和SARS中的复制-
仓鼠中的CoV-2感染。我们将在特定目标1中通过评估modRNA的作用来检验这一假设。
在人和鼠细胞系中对IAV的作用,随后在小鼠中进行体内测试。在具体目标2中,我们将评估
modRNA在人类和仓鼠细胞系中对SARS-CoV-2的影响,随后在仓鼠中进行体内测试。
在第二阶段,我们建议测试不同的递送模式和modRNA的修饰,以优化最佳的递送模式。
有效递送和抗病毒保护。
全球流感市场价值约50亿美元,其中约五分之一与非疫苗有关
产品. Lab 11 Therapeutics的目标患者人群将是数亿人,
普通民众。考虑到IFN在控制许多病毒感染(ISG 15缺陷细胞)中的关键作用,
已经显示对照比WT细胞更有效地控制14种不同病毒的复制),
这里开发的针对IAV和SARS-CoV 2的先导药物可能也对其他病毒性疾病有效。
这将为Lab 11 Therapeutics提供许可不同产品的机会,
逐个指示的行动机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dusan Bogunovic其他文献
Dusan Bogunovic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dusan Bogunovic', 18)}}的其他基金
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)
纽约地区先天性缺陷免疫资源倡议联盟 (NY-ROYAL)
- 批准号:
10554965 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Immunologic and Predictive Features of MIS-C
MIS-C 的免疫学和预测特征
- 批准号:
10667530 - 财政年份:2022
- 资助金额:
$ 25.59万 - 项目类别:
Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome
SARS-CoV-2 介导的 I 型 IFN 拮抗作用在唐氏综合症患者中的作用
- 批准号:
10158984 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10206016 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10058607 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10120982 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10443794 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10655435 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10461962 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10681411 - 财政年份:2020
- 资助金额:
$ 25.59万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists